History of cosmetic botulinum toxin

3 History of cosmetic botulinum toxin






Introduction


The discovery of ‘sausage poison’ and subsequent identification of Clostridium botulinum as the bacterium responsible has had an enormous and lasting impact on the field of cosmetic dermatology. As is often the case in medicine, a series of serendipitous discoveries – coupled with astute clinical observations – unlocked the potential of botulinum toxin (BoNT) and led to significant medical gains (Tables 3.1 and 3.2). Once hailed as a promising breakthrough for a handful of muscular disorders, BoNT has since become a veritable mainstay of the cosmetic practitioner, its popularity growing exponentially to become one of the most requested procedures in facial rejuvenation.


Table 3.1 Timeline of clinical discovery






























Late 1700s Outbreaks of deadly illness from contaminated foods sweeps across Europe
1793 Biggest outbreak in Wildebrad, Southern Germany
1811 ‘Prussic acid’ named as culprit in sausage poisoning
1822 Dr Justinus Kerner publishes monograph of ‘sausage poison’ and accurately describes botulism
1895 Professor Emile Pierre Van Ermengem identifies Clostridium botulinum as causative agent of botulism
1895–1915 Seven serotypes of toxins are recognized
1928 Dr Herman Sommer isolates most potent serotype: BoNT-A
1946 Carl Lamanna and James Duff develop concentration and crystallization techniques subsequently used by Dr Edward J. Schantz at Fort Detrick, Maryland, for possible biological weapon
1972 Dr Schantz takes his research to the University of Wisconsin, where he produces the large batch of BoNT-A that remained in clinical use until December 1997

Table 3.2 Timeline of therapeutic development and use





















Late 1960s–early 1970s Dr Alan Scott begins animal experimentation with BoNT-A supplied by Dr Schantz
1973 Dr Scott publishes the first report of BoNT-A in primates
1978 FDA grants approval to begin testing small amounts of the toxin (Oculinum) in human volunteers
1980 Landmark paper demonstrating that BoNT-A corrects gaze misalignment in humans
1988 Allergan Inc. acquires rights to distribute Dr Scott’s Oculinum in the United States
1989– FDA approves BoNT-A for the non-surgical correction of strabismus, blepharospasm, hemifacial spasm, and Meige syndrome in adults
Clinical use expands to include treatment of cervical dystonia and spasmodic torticollis
Allergan purchases Dr Scott’s company and renames the toxin Botox®


Serendipitous discovery


By the late 1980s, nearly 10 000 patients had received injections of BoNT type A (BoNT-A; then called ‘Oculinum’ and distributed to qualified injectors by Dr Alan Scott of the Smith Kettlewell Institute of Visual Sciences, San Francisco, CA) for the treatment of strabismus, benign essential blepharospasm, and hemifacial spasm (Smith Kettlewell 1990.) Many of these patients had received multiple injections with no evidence of antibody formation or systemic complications over 6 years of continued use. In Vancouver, British Columbia, ophthalmologist Dr Jean Carruthers noticed a remarkable and unexpected effect in the brow of a patient treated for blepharospasm: a noticeable reduction in the appearance of glabellar furrows, giving her a more serene, untroubled expression. Dr Carruthers discussed the observation with her dermatologist spouse, Dr Alastair Carruthers, who was attempting to soften the forehead wrinkles of his patients using soft-tissue-augmenting agents available in the eighties.


Case Study 1


Mrs. LW, 50-years-old, had suffered for 20 years from severe bilateral spasms and twitches of her eyelids on both sides. Despite her normal visual acuities, she was unable to drive her car and apprehensive about crossing the street. Her clerical job had become increasingly difficult to perform; her eyelids would spasm and close without warning, worsening toward the end of the working day. Treatment with 30 units of onabotulinumtoxinA (Botox®) on each side resulted in almost complete symptom relief for approximately 3 months. In addition, she noticed that her brow and face appeared more relaxed, and her friends commented about how ‘fresh’ and attractive she looked. The deep frown lines between her brows appeared to efface, and her husband thought she looked less intense and angry. At her next appointment, Mrs. LW expressed concern when her doctor (JC) did not treat the medial ends of her eyebrows. When her doctor explained that she had not observed any spasm in those areas, Mrs. LW said: ‘Every time you treat me there, I get this beautiful, untroubled expression.’ It was the birth of the realization that onabotulinumtoxinA could be helpful in other patients with similar glabellar folds and medial brow ptosis.



Stay updated, free articles. Join our Telegram channel

Mar 12, 2016 | Posted by in General Surgery | Comments Off on History of cosmetic botulinum toxin

Full access? Get Clinical Tree

Get Clinical Tree app for offline access